CSF2 and prostate carcinoma: A GM-CSF gene-transfected allogeneic tumor cell vaccine (GVAX), which is based on prostate cancer cells given in combination with ipilimumab, has recently been shown (NCT01510288) to be safe and tolerable in patients affected by metastatic castration-resistant prostate cancer that had not been previously treated with chemotherapy [119].